MXPA04005891A - Proteinas envolventes del virus de hepatitis c purificadas para diagnostico y uso terapeutico. - Google Patents
Proteinas envolventes del virus de hepatitis c purificadas para diagnostico y uso terapeutico.Info
- Publication number
- MXPA04005891A MXPA04005891A MXPA04005891A MXPA04005891A MXPA04005891A MX PA04005891 A MXPA04005891 A MX PA04005891A MX PA04005891 A MXPA04005891 A MX PA04005891A MX PA04005891 A MXPA04005891 A MX PA04005891A MX PA04005891 A MXPA04005891 A MX PA04005891A
- Authority
- MX
- Mexico
- Prior art keywords
- relates
- diagnostic
- envelope proteins
- present
- therapeutic use
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 241000711549 Hepacivirus C Species 0.000 title 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 title 1
- 238000010504 bond cleavage reaction Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 108700008783 Hepatitis C virus E1 Proteins 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 230000002934 lysing effect Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se relaciona con un metodo para purificar proteinas envolventes oligomericas unicas o especificas del HCV recombinantes seleccionadas del grupo que consiste de E1 y/o E2 y/o E1/E2, caracterizado porque tras la lisis las celulas hospederas transformadas para aislar la proteina expresada de manera recombinante se lleva a cabo un paso de escision o reduccion del enlace disulfuro con un agente para escindir el enlace disulfuro. La presente invencion tambien se relaciona con una composicion aislada por ese metodo. La presente invencion tambien se relaciona con la aplicacion para diagnostico y terapeutica de esas composiciones. Ademas. La invencion se relaciona con el uso de la proteina el de HCV y peptidos para pronosticar y verificar la efectividad clinica y/o resultado clinico del tratamiento del HCV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2051001A | 2001-12-18 | 2001-12-18 | |
| US41835802P | 2002-10-16 | 2002-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04005891A true MXPA04005891A (es) | 2004-09-13 |
Family
ID=26693530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04005891A MXPA04005891A (es) | 2001-12-18 | 2004-06-16 | Proteinas envolventes del virus de hepatitis c purificadas para diagnostico y uso terapeutico. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1461080A2 (es) |
| JP (1) | JP2005516939A (es) |
| KR (1) | KR20040076869A (es) |
| CN (1) | CN1622828A (es) |
| AU (1) | AU2002361160B2 (es) |
| BR (1) | BR0215081A (es) |
| CA (1) | CA2468690A1 (es) |
| IL (1) | IL162236A0 (es) |
| MX (1) | MXPA04005891A (es) |
| NZ (1) | NZ533396A (es) |
| RU (1) | RU2319505C2 (es) |
| WO (1) | WO2003051912A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7108855B2 (en) | 1998-06-24 | 2006-09-19 | Innogenetics N.V. | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
| US7101561B2 (en) | 2000-12-01 | 2006-09-05 | Innogenetics N.V. | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
| WO2002085932A2 (en) | 2001-04-24 | 2002-10-31 | Innogenetics N.V. | Constructs and methods for expression of recombinant hcv envelope proteins |
| FR2859221B1 (fr) * | 2003-08-28 | 2005-10-14 | Centre Nat Rech Scient | Vecteur de co-expression de domaines membranaires de proteines d'enveloppe d'un virus et utilisations |
| EP1574517A1 (en) | 2004-03-09 | 2005-09-14 | Innogenetics N.V. | HCV E1 comprising specific disulfide bridges |
| EP1809773B1 (en) * | 2004-10-18 | 2014-07-16 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis c infection |
| CN100365124C (zh) * | 2005-10-27 | 2008-01-30 | 云南大学 | 一段丙型肝炎病毒特异性cDNA序列的应用 |
| WO2009030872A1 (en) * | 2007-09-07 | 2009-03-12 | Mats Axel Atterdag Persson | Materials and methods for the treatment of hepatitis c |
| SI2285408T1 (sl) | 2008-06-05 | 2019-02-28 | Ablynx N.V. | Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni |
| NZ597314A (en) | 2009-06-05 | 2013-07-26 | Ablynx Nv | Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections |
| EP2507262A1 (en) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| EP2720716B1 (en) | 2011-06-14 | 2018-03-21 | Globeimmune, Inc. | Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection |
| RU2570553C2 (ru) * | 2013-11-20 | 2015-12-10 | Федеральное бюджетное учреждение "Всероссийский научно-исследовательский институт лесоводства и механизации лесного хозяйства (ФБУ ВНИИЛМ) | Способ очистки вирусных полиэдров |
| CN104327170A (zh) * | 2014-05-16 | 2015-02-04 | 中国疾病预防控制中心病毒病预防控制所 | 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用 |
| CN107002079A (zh) | 2014-09-17 | 2017-08-01 | 衣阿华大学研究基金会 | 作为免疫调节剂和疫苗组分的病毒rna区段 |
| US20190284230A1 (en) * | 2016-09-29 | 2019-09-19 | Macfarlane Burnet Institute For Medical Research And Public Health Limited | Assembled glycoproteins |
| WO2020117760A1 (en) * | 2018-12-03 | 2020-06-11 | Duke University | Purification method for recombinant proteins and nanoparticles |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0992580T3 (da) * | 1993-11-04 | 2005-07-11 | Innogenetics Nv | Epitoper på human T-celler, som er immundominante for hepatitis C-virus |
| NZ508797A (en) * | 1998-06-24 | 2004-02-27 | Innogenetics N | Particles of HCV envelope proteins: use for vaccination |
-
2002
- 2002-12-18 RU RU2004116914/15A patent/RU2319505C2/ru not_active IP Right Cessation
- 2002-12-18 KR KR10-2004-7009720A patent/KR20040076869A/ko not_active Application Discontinuation
- 2002-12-18 CN CNA028282027A patent/CN1622828A/zh active Pending
- 2002-12-18 EP EP02796675A patent/EP1461080A2/en not_active Withdrawn
- 2002-12-18 WO PCT/EP2002/014480 patent/WO2003051912A2/en active IP Right Grant
- 2002-12-18 CA CA002468690A patent/CA2468690A1/en not_active Abandoned
- 2002-12-18 AU AU2002361160A patent/AU2002361160B2/en not_active Expired - Fee Related
- 2002-12-18 NZ NZ533396A patent/NZ533396A/en unknown
- 2002-12-18 JP JP2003552792A patent/JP2005516939A/ja active Pending
- 2002-12-18 BR BR0215081-6A patent/BR0215081A/pt not_active IP Right Cessation
- 2002-12-18 IL IL16223602A patent/IL162236A0/xx unknown
-
2004
- 2004-06-16 MX MXPA04005891A patent/MXPA04005891A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1622828A (zh) | 2005-06-01 |
| KR20040076869A (ko) | 2004-09-03 |
| NZ533396A (en) | 2005-04-29 |
| AU2002361160B2 (en) | 2008-07-03 |
| EP1461080A2 (en) | 2004-09-29 |
| BR0215081A (pt) | 2004-10-19 |
| RU2319505C2 (ru) | 2008-03-20 |
| WO2003051912A9 (en) | 2004-07-15 |
| WO2003051912A3 (en) | 2004-03-04 |
| JP2005516939A (ja) | 2005-06-09 |
| CA2468690A1 (en) | 2003-06-26 |
| AU2002361160A1 (en) | 2003-06-30 |
| WO2003051912A2 (en) | 2003-06-26 |
| IL162236A0 (en) | 2005-11-20 |
| RU2004116914A (ru) | 2005-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1996004385A3 (en) | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use | |
| MXPA04005891A (es) | Proteinas envolventes del virus de hepatitis c purificadas para diagnostico y uso terapeutico. | |
| Usami et al. | A 28-kDa protein with disintegrin-like structure (jararhagin-C) purified from Bothrops jararaca venom inhibits collagen-and ADP-induced platelet aggregation | |
| Randolph et al. | Amino acid sequence of fibrolase, a direct‐acting fibrinolytic enzyme from agkistrodon contortrix contortrix venom | |
| ATE286067T1 (de) | Hcv hüllproteine partikel : verwendung für therapeutische impfung | |
| WO2002086100A3 (en) | Expression of core-glycosylated hcv envelope proteins in yeast | |
| DE60324552D1 (en) | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren | |
| CA2404163A1 (en) | Production of recombinant blood clotting factors in human cell lines | |
| EP1484339A3 (en) | Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same | |
| JP2004536077A5 (es) | ||
| IL210455A (en) | A polypeptide for reducing mammalian signaling 13il, and using a polypeptide to produce a drug for up-regulating gene expression 2ra13-il in mammals | |
| WO2004085633A8 (en) | A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof | |
| Gu et al. | Identification of salivary proteins inhibiting herpes simplex virus 1 replication | |
| MXPA05005202A (es) | Vacuna. | |
| EP1702068A4 (en) | APPROVED INTERLEUKINE-10 AND ITS USES | |
| WO2002055548A3 (en) | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use | |
| EP1613345A4 (en) | COMPOSITIONS AND METHODS WITH THE RESPIRATORY SYNCYTIAL VIRUS SUB-GROUP B STAMM 9320 | |
| EP1866334B1 (en) | Inhibitor of endogenous human interferon - gamma | |
| ATE411812T1 (de) | Peptide zur behandlung von infektionen mit dem herpes-virus | |
| Holtet et al. | Receptor‐binding domain of human α2‐macroglobulin Expression, folding and biochemical characterization of a high‐affinity recombinant derivative | |
| WO2004014936A3 (fr) | Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications. | |
| CA2480904A1 (en) | Prothrombin activating protein | |
| WO2003064446A3 (en) | Plasma protein-binding peptides from bacterial curli | |
| JP2005502327A5 (es) | ||
| Movat et al. | Neutrophil generation of permeability enhancing peptides from plasma substrates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |